Cancer Genetics, Inc. Announces a Global Partnership with BARC Global Central Laboratory to Offer Comprehensive Clinical Trial and Companion Diagnostic Solutions for the Oncology Industry - Seite 2

"With BARC and CGI focused on the same goal of providing patients, physicians and pharmaceutical companies with the best healthcare service, this partnership will meet the most demanding standards in personalized medicine worldwide. It will satisfy the enormous need among biotech and pharmaceutical companies for more efficient and comprehensive testing solutions by integrating CGI's specialized, genomic testing with BARC's laboratory solutions and global network. Providing better and more integrated access to both US and European markets is a critical need in oncology trials that are becoming more global and increasing in cost and complexity," said Panna Sharma, CEO of Cancer Genetics.

With later stage clinical research and trials shifting overseas, the partnership will provide clients access to combined expertise on a global basis - ranging from complex, oncology-focused genomic testing to core central laboratory analysis, project and data management and sample logistics. It will address the increased pressure regarding turn-around time (TAT) due to increasingly globalized studies. The combined expertise in biomarker discovery and companion diagnostics development will become critical for offering the development and validation of oncology biomarkers and for implementing technology transfers that support the precision oncology efforts of with global customers.

Based on recent industry reports by PhRMA, an industry organization representing the country's leading biopharmaceutical research companies, per-patient clinical trial costs are estimated to have averaged $36,500 during Phase III trials, with oncology trials showing the highest average per-patient cost of $59,500 during Phase III. The CGI and BARC combination is expected to help lower clinical trial costs and complexity by facilitating access to international markets, implementing harmonized protocols and data integration standards across lab and trials and reducing the complexities of workflow across sites, sample management and storage and logistics.

Oncology testing services are central to CGI's business model and are also a core focus area for BARC. Together, the two companies will leverage their respective expertise to provide key insights to the oncology drug development and clinical trial process, one that is expected to reach over $5.4 billion in spending on oncology trials that need biomarker and genomic testing support.